PMID- 8749778
OWN - NLM
STAT- MEDLINE
DCOM- 19961023
LR  - 20071114
IS  - 0196-4763 (Print)
IS  - 0196-4763 (Linking)
VI  - 22
IP  - 4
DP  - 1995 Dec 15
TI  - Aneuploidy in breast cancer: a fluorescence in situ hybridization study.
PG  - 282-91
AB  - Although ploidy is associated with the development and progression of most breast 
      cancers, the value of flow cytometric ploidy as a clinical prognostic factor 
      remains controversial. The technique of fluorescence in situ hybridization (FISH) 
      can be used not only to determine overall ploidy, but also to assess the 
      over-representation or under-representation of specific chromosomes in interphase 
      cells. This information may be of prognostic value. We studied 84 primary breast 
      cancers and 20 metastatic tumors by FISH, using chromosome-specific fluorescent 
      centromeric probes. Of these, 100 cases were also studied by DNA flow cytometry. 
      The FISH studies were concordant with DNA flow cytometry with regard to 
      distinguishing aneuploid from diploid tumors in 78% of cases. The FISH data 
      suggested that aneuploidy arises by a process of chromosome complement doubling 
      with subsequent chromosome loss. In tumors that exhibited evidence of more than 
      one round of chromosome complement doubling, the selective accumulation of 
      multiple copies of specific chromosomes or chromosome segments was common. 
      Multiple copies of chromosomes centromeres 1, 3, and 17 were accumulated 
      selectively in the cells of individual tumors more frequently than chromosomes 
      centromeres 7, 11, and 16. Multiple copies of chromosomes centromeres 10 and 20 
      were selectively accumulated only rarely, if at all. Aneuploidy in breast cancer 
      can be divided into distinct stages using fluorescence in situ hybridization 
      techniques. The stages of aneuploidy provide potential landmarks in the genetic 
      evolution of this disease with possible links to chromosome-specific evolutionary 
      changes.
FAU - Shackney, S E
AU  - Shackney SE
AD  - Laboratory of Cancer Cell Biology and Genetics, Allegheny-Singer Research 
      Institute, Pittsburgh, Pennsylvania 15212-4772, USA.
FAU - Singh, S G
AU  - Singh SG
FAU - Yakulis, R
AU  - Yakulis R
FAU - Smith, C A
AU  - Smith CA
FAU - Pollice, A A
AU  - Pollice AA
FAU - Petruolo, S
AU  - Petruolo S
FAU - Waggoner, A
AU  - Waggoner A
FAU - Hartsock, R J
AU  - Hartsock RJ
LA  - eng
GR  - 1 RO1 CA55230/CA/NCI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Cytometry
JT  - Cytometry
JID - 8102328
RN  - 0 (DNA, Neoplasm)
SB  - IM
MH  - Aged
MH  - *Aneuploidy
MH  - Breast Neoplasms/*genetics
MH  - *Chromosome Aberrations
MH  - *Chromosome Disorders
MH  - DNA, Neoplasm/genetics
MH  - Data Interpretation, Statistical
MH  - Female
MH  - Flow Cytometry
MH  - Gene Dosage
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Lymphocytes/cytology/physiology
MH  - Middle Aged
MH  - S Phase/genetics
MH  - Specimen Handling
EDAT- 1995/12/15 00:00
MHDA- 1995/12/15 00:01
CRDT- 1995/12/15 00:00
PHST- 1995/12/15 00:00 [pubmed]
PHST- 1995/12/15 00:01 [medline]
PHST- 1995/12/15 00:00 [entrez]
AID - 10.1002/cyto.990220404 [doi]
PST - ppublish
SO  - Cytometry. 1995 Dec 15;22(4):282-91. doi: 10.1002/cyto.990220404.